Lissandra Dal Lago - Concepedia

Author

Lissandra Dal Lago

Also Known As

L Dal Lago, L Lago, L dal Lago, L. D. Lago, L. DAL LAGO, L. Dal Lago, L. Dal Lago⁎, L.D. Lago, Leonardo Dingo do Lago, Lissandra D Lago

117

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

Institut Jules Bordet Université Libre de Bruxelles KU Leuven European Organisation for Research and Treatment of Cancer Champalimaud Foundation

About

Lissandra Dal Lago is an author at Institut Jules Bordet specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	1.4K
2	Health Sciences	3	3	546
3	Nursing	2	2	53
4	Education	1	1	16
5	Biostatistics	1	1	125

Lissandra Dal Lago

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard D. Gelber, Martine Piccart, The Lancet Breast OncologyHealth SciencesMedicineClinical TrialsBreast Cancer	2013	498
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program Fátima Cardoso, John M.S. Bartlett, Leen Slaets, Annals of Oncology Eortc 10085/Tbcrc/big/nabcgBreast OncologyMedicineGynecologyBreast Imaging	2017	381
Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group Hans Wildiers, Konstantinos Tryfonidis, Lissandra Dal Lago, The Lancet Oncology Breast OncologyOncologyMetronomic TherapyBreast CancerMetronomic Chemotherapy	2018	126
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial Hervé Bonnefoi, Martine Piccart, Jan Bogaerts, The Lancet Oncology Tp53 StatusBreast OncologyMedicineRandomised Phase 3Pathology	2011	125
Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study Sérgio D. Simon, José Bines, Gustavo Werutsky, The Breast Breast OncologyCancer EpidemiologyMedicineEpidemiology Of CancerPathology	2019	112
Phase II Trial of Cisplatin Plus Decitabine, a New DNA Hypomethylating Agent, in Patients With Advanced Squamous Cell Carcinoma of the Cervix Paula R. Pohlmann, Luciane Pons DiLeone, Anna Cancella, American Journal of Clinical Oncology	2002	86
Correction for chromosome-17 is critical for the determination of true <i>Her-2/neu</i> gene amplification status in breast cancer Lissandra Dal Lago, Virginie Durbecq, Christine Desmedt, Molecular Cancer Therapeutics	2006	72
Gastrin-Releasing Peptide Receptor Expression in Lung Cancer Jane Mattei, Rosane Duarte Achcar, C. Cano, Archives of Pathology & Laboratory Medicine	2013	64
Drugs prescribed for patients hospitalized in a geriatric oncology unit: Potentially inappropriate medications and impact of a clinical pharmacist C. Deliens, Gaétane Deliens, O. Filleul, Journal of Geriatric Oncology Geriatric OncologyOncologyGeriatricsMedicinePatient Safety	2016	55
The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters Barbara Brouwers, Sigrid Hatse, Lissandra Dal Lago, Oncotarget	2016	52

Page 1